Results for tag: "Noacs"

NOACs (Novel Oral Anticoagulants) are a class of drugs used to treat cardiovascular diseases such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. They are used to reduce the risk of stroke and other cardiovascular events. NOACs are a relatively new class of drugs, and are increasingly being used in place of traditional anticoagulants such as warfarin. NOACs have several advantages over warfarin, including fewer dietary restrictions, fewer drug interactions, and fewer monitoring requirements. NOACs are becoming increasingly popular in the cardiovascular drugs market, as they offer a more convenient and effective treatment option for patients. They are also being used in combination with other drugs to treat more complex cardiovascular conditions. Some of the major companies in the NOACs market include Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Pfizer, and Sanofi. Show Less Read more